Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 5, 2012, Pages 420-427

  Wu, Weihui ^a,d   Huang, Jin ^b   Duan, Biyan ^a   Traficante, David C ^a   Hong, Haeyeon ^a   Risech, Martina ^a   Lory, Stephen ^b   Priebe, Gregory P ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NANKAI UNIVERSITY   (China)

Author keywords

IL 17; Pneumonia; Pseudomonas aeruginosa; Th17; Vaccine

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; CURDLAN; FPTA PROTEIN; FPVA, PROTEIN; OPRL PROTEIN; PILQ PROTEIN; POPB PROTEIN; TH17 STIMULATING PROTEIN VACCINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LUNG; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; SPLEEN; SPLEEN CELL; TH17 CELL; TYPE III SECRETION SYSTEM; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; MICE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; SPLEEN; TH17 CELLS; VACCINES, ATTENUATED;

EID: 84865810704     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201202-0182OC     Document Type: Article

References (49)

1. Sun HY, Fujitani S, Quintiliani R, Yu VL. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 2011;139:1172-1185.
2. Bendiak GN, Ratjen F. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med 2009;30:587-595.
3. Pier GB. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen. Carbohydr Res 2003;338:2549-2556. (Pubitemid 37509953)
4. Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun 2009;77:2356-2366.
5. Baumann U, Mansouri E, von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 2004; 22:840-847. (Pubitemid 38177384)
6. Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, Wiener-Kronish JP, Frank DW. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999;5:392-398. (Pubitemid 29180576)
7. Donta ST, Peduzzi P, Cross AS, Sadoff J, Haakenson C, Cryz SJ Jr, Kauffman C, Bradley S, Gafford G, Elliston D, et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J Infect Dis 1996;174:537-543. (Pubitemid 26299687)
8. Chen K, McAleer JP, Lin Y, Paterson DL, Zheng M, Alcorn JF, Weaver CT, Kolls JK. Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity 2011;35:997-1009.
9. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, Pier GB. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol 2008;181:4965-4975.
10. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010;33:530-541.
11. Telford JL. Bacterial genome variability and its impact on vaccine design. Cell Host Microbe 2008;3:408-416. (Pubitemid 351773100)
12. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816-1820.
13. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, Tettelin H, Brettoni C, Iacobini ET, Rosini R, et al . Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005;309:148-150. (Pubitemid 40934997)
14. Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect Immun 2007;75: 1916-1925. (Pubitemid 46559461)
15. Montor WR, Huang J, Hu Y, Hainsworth E, Lynch S, Kronish JW, Ordonez CL, Logvinenko T, Lory S, LaBaer J. Genome-wide study of Pseudomonas aeruginosa outer membrane protein immunogenicity using self-assembling protein microarrays. Infect Immun 2009;77:4877-4886.
16. Matsushita S, Takagi R, Hashimoto K, Higashi T. Qualitative evaluation of adjuvant activities and its application to Th2/17 diseases. Int Arch Allergy Immunol 2011;155:2-5.
17. Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA. Intranasal immunization promotes Th17 immune responses. J Immunol 2009;183: 6933-6938.
18. Leibundgut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007;8:630-638.
19. Wu W, Huang J, Traficante DC, Pier GB, Lory S, Priebe GP. Identification of Pseudomonas aeruginosa outer membrane proteins that induce Th17 responses in mice following intranasal immunization with a live-attenuated vaccine. Presented at the American Society for Microbiology Meeting. May 2010, San Diego, CA. Abstract E-1659.
20. Reichelt P, Schwarz C, Donzeau M. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif 2006;46:483-488.
21. Allewelt M, Coleman FT, Grout M, Priebe GP, Pier GB. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 2000;68:3998-4004. (Pubitemid 30434552)
22. Kim J, Ahn K, Min S, Jia J, Ha U, Wu D, Jin S. Factors triggering type III secretion in Pseudomonas aeruginosa. Microbiology 2005;151: 3575-3587. (Pubitemid 41632070)
23. Wu W, Jin S. PtrB of Pseudomonas aeruginosa suppresses the type III secretion system under the stress of DNA damage. J Bacteriol 2005; 187:6058-6068. (Pubitemid 41262803)
24. Broms JE, Forslund AL, Forsberg A, Francis MS. PcrH of Pseudomonas aeruginosa is essential for secretion and assembly of the type III translocon. J Infect Dis 2003;188:1909-1921. (Pubitemid 38064878)
25. Schoehn G, Di Guilmi AM, Lemaire D, Attree I, Weissenhorn W, Dessen A. Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in Pseudomonas. EMBO J 2003;22:4957-4967. (Pubitemid 37222017)
26. Bechtluft P, Nouwen N, Tans SJ, Driessen AJ. SecB-a chaperone dedicated to protein translocation. Mol Biosyst 2010;6:620-627.
27. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Wiener-Kronish JP. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001;183:1767-1774. (Pubitemid 32523239)
28. Vance RE, Rietsch A, Mekalanos JJ. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect Immun 2005;73:1706-1713. (Pubitemid 40470759)
29. Koh AY, Mikkelsen PJ, Smith RS, Coggshall KT, Kamei A, Givskov M, Lory S, Pier GB. Utility of in vivo transcription profiling for identifying Pseudomonas aeruginosa genes needed for gastrointestinal colonization and dissemination. PLoS ONE 2010;5:e15131.
30. Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol 2009;12:61-66.
31. Rao AR, Laxova A, Farrell PM, Barbieri JT. Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis. J Clin Microbiol 2009;47: 2483-2488.
32. Pirnay JP, Bilocq F, Pot B, Cornelis P, Zizi M, Van Eldere J, Deschaght P, Vaneechoutte M, Jennes S, Pitt T, et al. Pseudomonas aeruginosa population structure revisited. PLoS ONE 2009;4:e7740.
33. Pozuelo MJ, Jimenez PA, Valderrey AD, Fernandez-Olmos A, Canton R, Rotger R. Polymorphism of mucA and fpvA genes in Pseudomonas aeruginosa isolates from cystic fibrosis patients: co-existence of genetically different variants. Enferm Infecc Microbiol Clin 2011;29:26-31.
34. Priebe GP, Brinig MM, Hatano K, Grout M, Coleman FT, Pier GB, Goldberg JB. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect Immun 2002;70:1507-1517. (Pubitemid 34163430)
35. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 2009;7:654-665.
36. Frithz-Lindsten E, Holmstrom A, Jacobsson L, Soltani M, Olsson J, Rosqvist R, Forsberg A. Functional conservation of the effector protein translocators PopB/YopB and PopD/YopD of Pseudomonas aeruginosa and Yersinia pseudotuberculosis. Mol Microbiol 1998;29:1155-1165. (Pubitemid 28408839)
37. Goure J, Pastor A, Faudry E, Chabert J, Dessen A, Attree I. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. Infect Immun 2004;72:4741-4750. (Pubitemid 38989335)
38. Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun 2003;71:1453-1461. (Pubitemid 36254332)
39. Liu J, Feng Y, Yang K, Li Q, Ye L, Han L, Wan H. Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol Med Microbiol 2011;61:179-188.
40. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194:519-527. (Pubitemid 32835046)
41. Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, Flechtner JB, Higgins DE, Malley RT. (H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011;9:158-165.
42. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, Godinez I, Sankaran S, Paixao TA, Gordon MA, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008;14:421-428. (Pubitemid 351499394)
43. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008; 4:e1000159.
44. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-377. (Pubitemid 46745412)
45. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004;190:624-631. (Pubitemid 38982105)
46. Natale P, Brüser T, Driessen AJ. Sec- and Tat-mediated protein secretion across the bacterial cytoplasmic membrane-distinct translocases and mechanisms. Biochim Biophys Acta 2008;1778:1735-1756.
47. Mueller CA, Broz P, Muller SA, Ringler P, Erne-Brand F, Sorg I, Kuhn M, Engel A, Cornelis GR. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 2005;310:674-676. (Pubitemid 41528159)
48. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005;175:404-412. (Pubitemid 40884344)
49. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011;184:252-258.